These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 18790780)
1. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Stresemann C; Bokelmann I; Mahlknecht U; Lyko F Mol Cancer Ther; 2008 Sep; 7(9):2998-3005. PubMed ID: 18790780 [TBL] [Abstract][Full Text] [Related]
2. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. Hagemann S; Heil O; Lyko F; Brueckner B PLoS One; 2011 Mar; 6(3):e17388. PubMed ID: 21408221 [TBL] [Abstract][Full Text] [Related]
3. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome. Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056 [TBL] [Abstract][Full Text] [Related]
4. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies. Hackanson B; Robbel C; Wijermans P; Lübbert M Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549 [TBL] [Abstract][Full Text] [Related]
5. DNA methyltransferases as targets for cancer therapy. Ghoshal K; Bai S Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710 [TBL] [Abstract][Full Text] [Related]
6. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Leone G; Voso MT; Teofili L; Lübbert M Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280 [TBL] [Abstract][Full Text] [Related]
7. Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia. Szmigielska-Kapłon A; Robak T Curr Cancer Drug Targets; 2011 Sep; 11(7):837-48. PubMed ID: 21762079 [TBL] [Abstract][Full Text] [Related]
8. DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML. Lund K; Cole JJ; VanderKraats ND; McBryan T; Pchelintsev NA; Clark W; Copland M; Edwards JR; Adams PD Genome Biol; 2014 Aug; 15(8):406. PubMed ID: 25315154 [TBL] [Abstract][Full Text] [Related]
9. The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells. Hummel-Eisenbeiss J; Hascher A; Hals PA; Sandvold ML; Müller-Tidow C; Lyko F; Rius M Mol Pharmacol; 2013 Sep; 84(3):438-50. PubMed ID: 23814180 [TBL] [Abstract][Full Text] [Related]
10. Azacytidine inhibits the proliferation of human promyelocytic leukemia cells (HL60) by demethylation of MGMT, DAPK and p16 genes. Su Y; Xu H; Xu Y; Yu J; Xian Y; Luo Q Hematology; 2012 Jan; 17(1):41-6. PubMed ID: 22549447 [TBL] [Abstract][Full Text] [Related]
11. Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies. Orsini P; Impera L; Parciante E; Cumbo C; Minervini CF; Minervini A; Zagaria A; Anelli L; Coccaro N; Casieri P; Tota G; Brunetti C; Ricco A; Carluccio P; Specchia G; Albano F Diagn Pathol; 2018 Dec; 13(1):98. PubMed ID: 30579366 [TBL] [Abstract][Full Text] [Related]
12. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Schaefer M; Hagemann S; Hanna K; Lyko F Cancer Res; 2009 Oct; 69(20):8127-32. PubMed ID: 19808971 [TBL] [Abstract][Full Text] [Related]
13. Digging deep into "dirty" drugs - modulation of the methylation machinery. Pleyer L; Greil R Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693 [TBL] [Abstract][Full Text] [Related]
14. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Link PA; Baer MR; James SR; Jones DA; Karpf AR Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910 [TBL] [Abstract][Full Text] [Related]
15. 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. Ghanim V; Herrmann H; Heller G; Peter B; Hadzijusufovic E; Blatt K; Schuch K; Cerny-Reiterer S; Mirkina I; Karlic H; Pickl WF; Zöchbauer-Müller S; Valent P Blood; 2012 May; 119(18):4242-52. PubMed ID: 22438247 [TBL] [Abstract][Full Text] [Related]
16. [Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs]. Ye XS; Liu T; Cui X; Meng WT; Xi YM Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jan; 38(1):57-9. PubMed ID: 17294728 [TBL] [Abstract][Full Text] [Related]
17. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Stresemann C; Lyko F Int J Cancer; 2008 Jul; 123(1):8-13. PubMed ID: 18425818 [TBL] [Abstract][Full Text] [Related]
18. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. Hollenbach PW; Nguyen AN; Brady H; Williams M; Ning Y; Richard N; Krushel L; Aukerman SL; Heise C; MacBeth KJ PLoS One; 2010 Feb; 5(2):e9001. PubMed ID: 20126405 [TBL] [Abstract][Full Text] [Related]
19. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Gore SD; Baylin S; Sugar E; Carraway H; Miller CB; Carducci M; Grever M; Galm O; Dauses T; Karp JE; Rudek MA; Zhao M; Smith BD; Manning J; Jiemjit A; Dover G; Mays A; Zwiebel J; Murgo A; Weng LJ; Herman JG Cancer Res; 2006 Jun; 66(12):6361-9. PubMed ID: 16778214 [TBL] [Abstract][Full Text] [Related]
20. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]